Description
ICG 001 | 27752-3 | Gentaur US, UK & Europe Disrtribition
Category: Inhibitors / Activators/Other
Application: N/A
Background: ICG001 selectively inhibits colon carcinoma cell lines (SW480 and HCT-116 cells) but not normal colonic epithelial cells (CCD-841Co). It is also efficacious in the Min mouse and nude mouse xenograft models of colon cancer. ICG-001 is a potent inhibitor of GBM stem cells in culture. ICG001 selectively inhibits Wnt/beta-catenin/CREB binding protein (CBP) signaling to reverses pulmonary fibrosis and ameliorate experimental dermal fibrosis in experimental models. ICG001 is currently in clinical trials for colon cancer and leukemias.
Description: CG001 is a small molecule inhibitor that targets Wnt/β-catenin pathway. It inhibits TCF/β-catenin mediated transcription by competing with β-catenin for CBP (CREB binding protein) but not p300 binding with an IC50 of 3 µM. It can be used to specifically evaluate the role of CBP/beta-catenin association on WNT signaling and cell physiology.
Product Type: Inhibitor
Shippement Condition: Room temp. (continental US) or gel packs
